Table 1.

Main clinical trials assessing the efficacy and safety of SGLT2-inhibitors in HF.

Trial name	Regimen	Number of patients	Primary outcome(s)	Results
CANVAS⁶³	Canagliflozin 100 or 300 mg	10142	composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke	HR:0.86; 95%CI: 0.75 to 0.97; P<0.001 for non-inferiority; P=0.02 for superiority
CREDENCE⁸²	Canagliflozin 100 mg	4401	composite of end-stage kidney disease, a doubling of the serum creatinine level, or death from renal or cardiovascular causes	HR:0.70; 95%CI: 0.59 to 0.82; P=0.00001
DAPA-CKD⁵⁷	Dapagliflozin 10 mg	4304	composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes	HR:0.61; 95%CI: 0.51 to 0.72; P<0.001
DAPA-HF⁸³	Dapagliflozin 10 mg	4744	composite of cardiovascular death or episode of worsening HF	HR:0.74; 95%CI: 0.65 to 0.85; P<0.001
DECLARE-TIMI 58⁸⁴	Dapagliflozin 10 mg	17160	composite of MACE and cardiovascular death or hospitalization for HF	HR:0.83; 95%CI: 0.73 to 0.95; P=0.005
EMPA-REG OUTCOME reported⁶²	Empagliflozin 10 or 25 mg	7020	composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke	HR:0.86; 95.02%CI: 0.74 to 0.99; P=0.04
EMPEROR-REDUCED⁸⁵	Empagliflozin 10 mg	3730	composite of adjudicated cardiovascular death or hospitalization for HF	HR:0.76; 95%CI: 0.67–0.87; P<0.0001
VERTIS-CV¹³	Ertugliflozin 5 or 15 mg	8246	composite of MACE	HR:0.97; 95.6%CI: 0.85 to 1.11; P<0.001

CI: Confidence Interval; GFR: Glomerular Filtration Rate; HF: Heart Failure; HR: Hazard Ratio; MACE: Major Adverse Cardiovascular Events; MI: Myocardial Infarction.